Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label Adaptive Design Dose Finding Study to Investigate Effect of Synthetic PreImplantation Factor (sPIF) in Patients With High Panel Reactive Antibodies

NCT03593421 is registered in ClinicalTrials.gov with Christopher O'Brien, MD as lead sponsor.

NCT NCT03593421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03593421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label Adaptive Design Dose Finding Study to Investigate Effect of Synthetic PreImplantation Factor (sPIF) in Patients With High Panel Reactive Antibodies
Lead sponsor
Christopher O'Brien, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
February 1, 2019
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

panel reactive antibodies